Abstract
The mammalian dim-light photoreceptor rhodopsin is a prototypic G protein coupled receptor (GPCR), interacting with the G protein, transducin, rhodopsin kinase, and arrestin. All of these proteins interact with rhodopsin at its cytoplasmic surface. Structural and modeling studies have provided in-depth descriptions of the respective interfaces. Overlap and thus competition for binding surfaces is a major regulatory mechanism for signal processing. Recently, it was found that the same surface is also targeted by small molecules. These ligands can directly interfere with the binding and activation of the proteins of the signal transduction cascade, but they can also allosterically modulate the retinal ligand binding pocket. Because the pocket that is targeted contains residues that are highly conserved across Class A GPCRs, these findings imply that it may be possible to target multiple GPCRs with the same ligand(s). This is desirable for example in complex diseases such as cancer where multiple GPCRs participate in the disease networks.
Keywords: G protein coupled receptors, allostery, conformational changes, docking, protein-protein interactions, Rhodopsin, drug discovery, cytoplasm, GPCR, crystal structure
Current Drug Targets
Title: The Cytoplasmic Rhodopsin-Protein Interface: Potential for Drug Discovery
Volume: 13 Issue: 1
Author(s): Naveena Yanamala, Eric Gardner, Alec Riciutti and Judith Klein-Seetharaman
Affiliation:
Keywords: G protein coupled receptors, allostery, conformational changes, docking, protein-protein interactions, Rhodopsin, drug discovery, cytoplasm, GPCR, crystal structure
Abstract: The mammalian dim-light photoreceptor rhodopsin is a prototypic G protein coupled receptor (GPCR), interacting with the G protein, transducin, rhodopsin kinase, and arrestin. All of these proteins interact with rhodopsin at its cytoplasmic surface. Structural and modeling studies have provided in-depth descriptions of the respective interfaces. Overlap and thus competition for binding surfaces is a major regulatory mechanism for signal processing. Recently, it was found that the same surface is also targeted by small molecules. These ligands can directly interfere with the binding and activation of the proteins of the signal transduction cascade, but they can also allosterically modulate the retinal ligand binding pocket. Because the pocket that is targeted contains residues that are highly conserved across Class A GPCRs, these findings imply that it may be possible to target multiple GPCRs with the same ligand(s). This is desirable for example in complex diseases such as cancer where multiple GPCRs participate in the disease networks.
Export Options
About this article
Cite this article as:
Yanamala Naveena, Gardner Eric, Riciutti Alec and Klein-Seetharaman Judith, The Cytoplasmic Rhodopsin-Protein Interface: Potential for Drug Discovery, Current Drug Targets 2012; 13 (1) . https://dx.doi.org/10.2174/138945012798868461
DOI https://dx.doi.org/10.2174/138945012798868461 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Development of Pro-Apoptotic Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Differential Proteomic Identification and Bioinformatics Analysis of Femoral Neck in Elderly Female Patients with Hyperuricaemia
Current Proteomics Photosensitizers Mediated Photodynamic Inactivation Against Virus Particles
Mini-Reviews in Medicinal Chemistry Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Current Cancer Therapy Reviews Patent Selections
Recent Patents on Biomarkers Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism Percutaneous Dilatational Tracheostomy - An Update
Current Respiratory Medicine Reviews NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Intercellular Crosstalk Via Extracellular Vesicles in Tumor Milieu as Emerging Therapies for Cancer Progression
Current Pharmaceutical Design Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors
Current Drug Targets Targeting the STAT Pathway in Head and Neck Cancer: Recent Advances and Future Prospects
Current Cancer Drug Targets Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals Flavonoids for Allergic Diseases: Present Evidence and Future Perspective
Current Pharmaceutical Design Therapeutic Potential, Synthesis, Patent Evaluation and SAR Studies of Thieno[3,2-d]pyrimidine Derivatives: Recent Updates
Current Drug Targets Brain Tumour Stem Cells: Implications for Cancer Therapy and Regenerative Medicine
Current Stem Cell Research & Therapy Targeting Plasmodium Falciparum Purine Salvage Enzymes: A Look At Structure-Based Drug Development
Infectious Disorders - Drug Targets Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Technologies for Translational Imaging Using Generators in Oncology
Recent Patents on Anti-Cancer Drug Discovery